Report: Strategies for Building Early-Stage Pipelines Through External Sources

Abstract

Introduction

Under tremendous pressure to refuel dwindling development pipelines and improve R&D productivity, pharmaceutical companies are seeking external sources of products and innovation. Biotech companies offer valuable technologies, targets, and compounds. Pharma companies best able to access these assets and adopt new business and R&D models to develop them will be most competitive.

Questions Answered in This Report

Pharmaceutical companies are seeking new ways to build early-stage pipelines. What strategies are available to companies to access early-stage products and technologies? What are the benefi ts and risks of these strategies? What factors drive decision making for choosing strategies?
External sources offer a variety of valuable early-stage assets. What types of assets are available for building early-stage pipelines? Which companies are the most useful sources of these assets? Which pharmaceutical companies are targeting particular types of companies and assets?
Recent high-value deals exemplify different strategies for accessing external sources for building up early-stage pipelines. What corporate strategies do these deals serve? What are the structure and value of these deals? How do these deals illuminate current industry trends and opportunities in building early-stage pipelines?

Scope

The need for innovation in building early-stage pipelines: R&D spending versus productivity, patent expirations, acquisition targets.
Strategies for accessing innovation: Mergers and acquisitions (M&As), corporate partnerships, academic collaborations.
Strategies for building pipelines through partnering: Development compounds, novel targets, technology platforms.
Select deal highlights in building early-stage pipelines: Novel product classes, diseasemodifying drugs, early-stage compounds, programs around novel targets, broad platform technologies, proprietary platform technologies, technologies for drug repositioning, product class diversifi cation.
Technologies of interest: RNA interference (RNAi), microRNA, large molecules, biologics, glycosylation, antisense, oligonucleotides, DNA vaccine immunotherapy, structurebased drug design, deuterium - based dugs.
Industry outlook: Restructuring internal R&D, need for corporate partnerships, reallocation of R&D resources, shifts in industry structure, novel ways to generate external innovation, corporate venture capital.

Mentioned in This Report

Ablynx
Acceleron Pharma
Adnexus
Affi ris
Alnylam Pharmaceuticals
Amgen
Apiptope
Archemix
Ardea Biosciences
Astellas Pharma
Astex Technology
AstraZeneca
Bayer Healthcare
Bayer Schering Pharma
Bayhill Therapeutics
Biogen Idec
Bioinvent
BiolineRX
Biotica Technology
Boehringer Ingelheim
Bristol-Myers Squibb
Catalyst Biosciences
Celgene
Celldex
Chroma Therapeutics
CoMentis
Concert Pharmaceuticals
Cougar Biotechnology
Cytokinetics
Cytos
Dyax
Dynavax
Eli Lilly
Ensemble Discovery
Epistem
Exelixis
Forma Therapeutics
Galapagos
Genentech
Genzyme
GlaxoSmithKline
GlycoFi
Idenix
Ikaria
Janssen Pharmaceutica
Johnson & Johnson
Kyowa Hakko Kogyo
Lpath Therapeutics
Maxygen
MedImmune
Merck
Merck KGaA
Merck Serono
Micromet
Millennium Pharmaceuticals
Mpex Pharmaceuticals
Neurosearch
Novartis
Oxford Biotherapeutics
Peptimmune
Pfi zer
Plexxikon
Portola Pharmaceuticals
Roche
Sanofi -Aventis
Santaris
Sirtris Pharmaeuticals
Symphogen
Tacere
Takeda Pharmaceuticals
Thrombogenics
Vitae Pharmaceuticals
Wyeth
Zydus Cadila
Zymogenetics